This trial is withdrawn!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Core: Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Module 1: Non-GCB Diffuse Large B-Cell Lymphoma
and you are
between 18 and 130
years old
1
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

This is a modular study of AZD2014 in combination with novel anti-cancer agents in patients with different subtypes of relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL). Module 1, a combination with ibrutinib in patients with non-germinal centre B-cell-like (non-GCB) DLBCL, will consist of Part A, a Phase I dose-finding arm in which the safety and tolerability of the combination will be assessed, and Part B, a Phase II dose-expansion phase to assess the efficacy of the combination.

Provided treatments

  • Drug: AZD2014
  • Drug: Ibrutinib
Tris trial is registered with FDA with number: NCT02780830. The sponsor of the trial is AstraZeneca and it is looking for 0 volunteers for the current phase.
Official trial title:
A Modular Phase I/IIa, Open-Label, Multicentre Study to Assess AZD2014 in Combination With Novel Anti-Cancer Agents in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (INHIBITOR Study)